Switch to:
Also traded in: Germany, Switzerland
» Details

Insider Trades

Latest Guru Trades with ORMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:LIFE, NAS:ARQL, AMEX:ATNM, NAS:NEPT, AMEX:XXII, NAS:AKTX, NAS:FLKS, NAS:ONS, NAS:AFMD, NAS:SNSS, NAS:CASI, NAS:CFRX, OTCPK:NEWG, NAS:AXSM, NAS:NOVN, NAS:TTNP, NAS:PIRS, OTCPK:SLNCF, OTCPK:ORGS, NAS:SBPH » details
Traded in other countries:OJU1.Germany, ORMP.Switzerland,
Oramed Pharmaceuticals Inc is a pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet.

Oramed Pharmaceuticals Inc was incorporated on April 12, 2002, under the laws of the state of Nevada. It is a pharmaceutical company engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, rectal application of insulin, use of oral ingestible capsules or tablets for delivery other polypeptides and use of rectal application for delivery of other polypeptides. It filed two additional provisional patents for a suppository application to its technology portfolio. It is subject to Federal and state laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export, use, and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with research are applicable to its activities.

Top Ranked Articles about Oramed Pharmaceuticals Inc

Something Strange Is Going On With Oral Insulin Novo Nordisk recently abandoned program despite promising results
Something is rotten in the state of Denmark. Read more...
» More Articles for ORMP

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 10.12
ORMP's Price-to-Owner-Earnings is ranked higher than
79% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. ORMP: 10.12 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ORMP' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.79  Med: 10.62 Max: 24.84
Current: 10.12
9.79
24.84
PB Ratio 3.43
ORMP's PB Ratio is ranked higher than
51% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. ORMP: 3.43 )
Ranked among companies with meaningful PB Ratio only.
ORMP' s PB Ratio Range Over the Past 10 Years
Min: 2.44  Med: 3.47 Max: 4.03
Current: 3.43
2.44
4.03
PS Ratio 64.38
ORMP's PS Ratio is ranked lower than
78% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. ORMP: 64.38 )
Ranked among companies with meaningful PS Ratio only.
ORMP' s PS Ratio Range Over the Past 10 Years
Min: 62.29  Med: 156.8 Max: 930
Current: 64.38
62.29
930
Price-to-Free-Cash-Flow 9.28
ORMP's Price-to-Free-Cash-Flow is ranked higher than
84% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. ORMP: 9.28 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ORMP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.98  Med: 9.74 Max: 22.28
Current: 9.28
8.98
22.28
Price-to-Operating-Cash-Flow 9.28
ORMP's Price-to-Operating-Cash-Flow is ranked higher than
83% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. ORMP: 9.28 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ORMP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.98  Med: 9.74 Max: 22.28
Current: 9.28
8.98
22.28
Current Ratio 6.44
ORMP's Current Ratio is ranked higher than
63% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ORMP: 6.44 )
Ranked among companies with meaningful Current Ratio only.
ORMP' s Current Ratio Range Over the Past 10 Years
Min: 0.13  Med: 8.19 Max: 67.68
Current: 6.44
0.13
67.68
Quick Ratio 6.44
ORMP's Quick Ratio is ranked higher than
65% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. ORMP: 6.44 )
Ranked among companies with meaningful Quick Ratio only.
ORMP' s Quick Ratio Range Over the Past 10 Years
Min: 0.13  Med: 8.19 Max: 67.68
Current: 6.44
0.13
67.68

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.40
ORMP's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. ORMP: -18.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ORMP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -44.9  Med: -18.4 Max: -7.6
Current: -18.4
-44.9
-7.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 8.58
ORMP's Price-to-Net-Current-Asset-Value is ranked lower than
67% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. ORMP: 8.58 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ORMP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.56  Med: 7.77 Max: 94.5
Current: 8.58
2.56
94.5
Price-to-Tangible-Book 3.41
ORMP's Price-to-Tangible-Book is ranked higher than
58% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ORMP: 3.41 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ORMP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.19  Med: 6.94 Max: 76.36
Current: 3.41
2.19
76.36
Price-to-Intrinsic-Value-Projected-FCF 22.07
ORMP's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
85% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. ORMP: 22.07 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ORMP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 21.93  Med: 31 Max: 40.06
Current: 22.07
21.93
40.06
Price-to-Median-PS-Value 0.41
ORMP's Price-to-Median-PS-Value is ranked higher than
85% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. ORMP: 0.41 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ORMP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.4  Med: 1.71 Max: 4.49
Current: 0.41
0.4
4.49
Earnings Yield (Greenblatt) % -12.32
ORMP's Earnings Yield (Greenblatt) % is ranked lower than
56% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. ORMP: -12.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ORMP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -666.7  Med: 0 Max: 9.3
Current: -12.32
-666.7
9.3

More Statistics

Revenue (TTM) (Mil) $1.25
EPS (TTM) $ -0.86
Beta0.74
Short Percentage of Float2.45%
52-Week Range $5.70 - 10.51
Shares Outstanding (Mil)13.28

Analyst Estimate

Aug17 Aug18
Revenue (Mil $) 1 1
EPS ($) -0.61 -1.01
EPS without NRI ($) -0.61 -1.01
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ORMP

Headlines

Articles On GuruFocus.com
While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever Feb 09 2017 
Something Strange Is Going On With Oral Insulin Dec 23 2016 

More From Other Websites
While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever Feb 09 2017
Oramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences Feb 07 2017
ORAMED PHARMACEUTICALS INC. Financials Jan 18 2017
Oramed reports 1Q loss Jan 12 2017
Oramed reports 1Q loss Jan 12 2017
ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report Jan 11 2017
3 Sleeper Biotechs That Could Bounce Back Strong in 2017 Dec 30 2016
Something Strange Is Going On With Oral Insulin Dec 23 2016
ORMP: Oramed Reports Positive Phase Ib Data for ORMD-0901 Nov 30 2016
Oramed's ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study Nov 29 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report Nov 25 2016
Oramed Receives Additional $4 Million Milestone Payment From HTIT Oct 06 2016
Oramed Receives Additional $4 Million Milestone Payment From HTIT Oct 06 2016
Oramed to Present at the Aegis Capital Growth Conference Sep 19 2016
Inside The FDA: Eli Lilly and Co (LLY) Jardiance Aims at Proving Cardiovascular Benefit in Diabetes,... Sep 09 2016
Oramed to Present at the Rodman & Renshaw Global Investment Conference Sep 07 2016
Inside the FDA: Why Sanofi SA (ADR) (SNY) IGlarLixi Was Delayed But Novo Nordisk A/S (ADR) (NVO)... Sep 06 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Aug 31 2016
Oramed (ORMP) Reports Additional Positive Data from Phase IIb ORMD-0801 Study Aug 11 2016
The Cryptic World of Oral Insulin, Novo Nordisk A/S (ADR) (NVO) vs Oramed Pharmaceuticals, Inc.... Aug 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK